<DOC>
	<DOCNO>NCT01337518</DOCNO>
	<brief_summary>This study evaluate experimental drug call EZN-4176 determine anticancer effect give patient advanced form prostate cancer call castration-resistant prostate cancer ( CRPC ) . Goals phase I study include find dose EZN-4176 safely give without serious side effect determine amount EZN-4176 give future study .</brief_summary>
	<brief_title>A Phase 1a/1b Study Evaluate Safety EZN-4176 , Adult Patients With Castration-Resistant Prostate Cancer</brief_title>
	<detailed_description>This study conduct two phase : - Phase 1a involve dose escalation determine maximum tolerate dose ( MTD ) . The MTD determine basis result safety evaluation . - Phase 1b involve cohort expansion one dose level determine recommend Phase 2 dose . The recommended Phase 2 dose , may differ MTD , determine basis result safety , activity , pharmacologic correlative study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>1 . Capable understand protocol requirement &amp; risk &amp; provide write informed consent 2 . Histologically cytologically confirm diagnosis metastatic prostate adenocarcinoma 3 . Ongoing gonadal androgendeprivation therapy LHRH analog orchiectomy . Patients without orchiectomy must receive effective LHRH analog therapy study 4 . Testosterone &lt; 50 ng/dL 5 . Progressive disease androgen deprivation 3 follow criterion : PSA evidence progressive prostate cancer ; PSA ≥ 5 ng/mL increase least 2 successive occasion , least 2 week apart . If confirmatory PSA &lt; screen PSA , additional test increase PSA need 6 . Patients receive antiandrogen agent part primary androgen ablation : disease progression stop antiandrogen agent . This disease progression define : 2 consecutive increase PSAs ≥ 2 week apart , document osseous soft tissue progression . Flutamide patient : least one PSAs ≥ 4 week stop flutamide . Bicalutamide nilutamide patient : least one PSA ≥ 6 week stop antiandrogen agent . 7 . Patients fail standard therapy , physician discussion , wish delay chemotherapy 8 . Age ≥ 18 yr 9 . ECOG Score : 01 10 . Albumin ≥3.0 g/dL 11 . ANC ≥ 1,500/µL 12 . Plts ≥ 75,000/µL 13 . Hgb ≥ 9.0 g/dL 14 . Serum Creat . ≤ 1.5xULN Calc Creat . clearance ≥ 60 mL/min 15 . Tot bili ≤ 1.5xULN 16 . AST ; ALT : ≤ 2.5xULN 1 . Prostate cancer adenocarcinoma , eg . neuroendocrine small cell histology 2 . Concurrent serious medical illness might interfere protocol compliance 3 . Known chronic infectious disease , eg . AIDS hepatitis 4 . Male patient reproductive capacity unwilling use method appropriate prevent pregnancy . In UK , doublebarrier contraception require . Patients continue use contraception 3 month stop EZN4176 due potential prolong halflife EZN4176 liver . 5 . History CNS tumor involvement 6 . Other hormonal therapy , eg . megestrol acetate ( Megace® ) , finasteride ( Proscar® ) , dutasteride ( Avodart® ) , herbal product know decrease PSA ( e.g. , saw palmetto , PCSPES , PCHOPE ) 7 . &gt; 10 mg/day prednisone equivalent systemic corticosteroid within 4 week first dose EZN4176 8 . Initiation bisphosphonates within 4 week enrollment . Patients receive stable dos bisphosphonates subsequent tumor progression may continue receive medication ; however , initiation bisphosphonates allow study . 9 . Therapy supplement complementary medicines/botanicals within 4 week first dose study drug , except combination follow : Conventional multivitamin supplement ; Selenium ; Lycopene ; Soy supplement 10 . Prior chemotherapy , immunotherapy , investigational therapeutic agent , therapy use treat cancer within 4 week ( 6 week prior treatment mitomycin C nitrosoureas ) first dose EZN4176 11 . Radiation radioactive treatment within 4 week first dose EZN4176 . Singlefraction palliative radiation allow within 2 week first dose EZN4176 12 . Lack recovery reversible side effect ( except alopecia Grade 1 2 neuropathy ) Grade 0 1 toxicity relate administration investigational therapeutic agent , chemotherapy , immunotherapy , radiotherapy , agent previously use treat cancer 13 . Current participation another clinical study investigational therapeutic agent and/or use investigational therapeutic drug ( include investigational use approve drug ) 30 day first dose EZN4176 14 . Inability comply study protocol 15 . Full anticoagulation therapy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Prostate Specific Antigen</keyword>
	<keyword>Castration Resistant Prostate Cancer</keyword>
	<keyword>Adenocarcinoma</keyword>
	<keyword>Androgen Receptor</keyword>
	<keyword>Metastases</keyword>
</DOC>